Tenaya Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.14
- Today's High:
- $3.36
- Open Price:
- $3.27
- 52W Low:
- $1.64
- 52W High:
- $8.091
- Prev. Close:
- $3.26
- Volume:
- 179911
Company Statistics
- Market Cap.:
- $255.17 million
- Book Value:
- 2.799
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -35.32%
- Return on Equity TTM:
- -62.45%
Company Profile
Tenaya Therapeutics Inc had its IPO on 2021-07-30 under the ticker symbol TNYA.
The company operates in the Healthcare sector and Biotechnology industry. Tenaya Therapeutics Inc has a staff strength of 141 employees.
Stock update
Shares of Tenaya Therapeutics Inc opened at $3.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.14 - $3.36, and closed at $3.19.
This is a -2.15% slip from the previous day's closing price.
A total volume of 179,911 shares were traded at the close of the day’s session.
In the last one week, shares of Tenaya Therapeutics Inc have slipped by -15.16%.
Tenaya Therapeutics Inc's Key Ratios
Tenaya Therapeutics Inc has a market cap of $255.17 million, indicating a price to book ratio of 0.8018 and a price to sales ratio of 0.
In the last 12-months Tenaya Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-126146000. The EBITDA ratio measures Tenaya Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tenaya Therapeutics Inc’s operating margin was 0% while its return on assets stood at -35.32% with a return of equity of -62.45%.
In Q2, Tenaya Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Tenaya Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.15 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tenaya Therapeutics Inc’s profitability.
Tenaya Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2143. Its price to sales ratio in the trailing 12-months stood at 0.
Tenaya Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $220.75 million
- Total Liabilities
- $20.92 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $208000
- Dividend Payout Ratio
- 0%
Tenaya Therapeutics Inc ended 2024 with $220.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $220.75 million while shareholder equity stood at $189.94 million.
Tenaya Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $20.92 million in other current liabilities, 7000.00 in common stock, $-344204000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $75.57 million and cash and short-term investments were $132.51 million. The company’s total short-term debt was $3,447,000 while long-term debt stood at $0.
Tenaya Therapeutics Inc’s total current assets stands at $138.91 million while long-term investments were $19.14 million and short-term investments were $56.94 million. Its net receivables were $0 compared to accounts payable of $8.48 million and inventory worth $0.
In 2024, Tenaya Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $208000.
Comparatively, Tenaya Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.19
- 52-Week High
- $8.091
- 52-Week Low
- $1.64
- Analyst Target Price
- $21.33
Tenaya Therapeutics Inc stock is currently trading at $3.19 per share. It touched a 52-week high of $8.091 and a 52-week low of $8.091. Analysts tracking the stock have a 12-month average target price of $21.33.
Its 50-day moving average was $4.53 and 200-day moving average was $4.09 The short ratio stood at 8.62 indicating a short percent outstanding of 0%.
Around 461.8% of the company’s stock are held by insiders while 6798% are held by institutions.
Frequently Asked Questions About Tenaya Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.